Shares Of Biotech Firm Wuxi
Tumble On Big Rise In Capital
Summary |
Mainland biotech firm says capital expenses to hit
US$200m, sparking downgrade by Goldman and the sharpest share
price fall in nine months
scmp.com | 17 April 2015